Voyager Therapeutics Gets Food and drug administration Clearance of IND Application for Gene Therapy Candidate VY-HTT01 for Treatment method of Huntington’s Disease

A single-Time Gene Treatment to be Evaluated in Patients with Early Huntington’s Disorder Initiation of

A single-Time Gene Treatment to be Evaluated in Patients with Early Huntington’s Disorder

Initiation of VYTAL Period 1/2 Scientific Trial at Many Websites Expected this Year

CAMBRIDGE, Mass., April 26, 2021 (World NEWSWIRE) — Voyager Therapeutics, Inc. (Nasdaq: VYGR), a clinical-phase gene treatment corporation creating everyday living-modifying treatment plans for serious neurological conditions, nowadays introduced the U.S. Foodstuff and Drug Administration (Food and drug administration) has removed its scientific keep on the company’s Investigational New Drug (IND) software for VY-HTT01, a gene therapy prospect for the therapy of Huntington’s condition (High definition), and verified that the business might carry on with its prepared Phase 1/2 clinical trial. The final decision was created subsequent a extensive critique of the Chemistry, Producing and Controls information and facts formerly submitted to the Food and drug administration. Voyager plans to initiate VYTAL, a Section 1/2 scientific demo of VY-HTT01, this year.

The selection by the Food and drug administration about our IND software for VY-HTT01 for Huntington’s sickness represents an crucial milestone for Voyager and is the end result of a long time of determination to producing an impactful new therapy to handle this devastating condition,” explained Andre Turenne, President and CEO of Voyager.

At present there are no disease-modifying therapies authorized for the cure of Huntington’s sickness, a deadly, inherited neurodegenerative condition brought on by poisonous acquire-of-function mutations in the huntingtin, or HTT, gene. Hd affects above 30,000 individuals in the U.S. by yourself, with symptom onset generally showing up involving the ages of 30 to 50. The illness is marked by progressive decrease of motor and cognitive features and a range of behavioral and psychiatric disturbances.

VY-HTT01 is a gene remedy built to minimize the expression of huntingtin, thus altering ailment development. VY-HTT01 is comprised of an adeno-associated virus capsid (AAV1) and a proprietary transgene that harnesses the canonical RNA interference pathway to selectively knock down ranges of HTT mRNA. Preclinical information in non-human primates demonstrated strong and durable reduction of HTT mRNA and protein and prevalent distribution of VY-HTT01 throughout the striatum and cortex, which are main locations of condition pathology.

“Our investigational gene remedy has been built to attain wide knockdown of HTT mRNA throughout the brain by means of a one-time MRI-guided neurosurgical shipping and delivery,” stated Omar Khwaja, CMO and Head of Analysis and Advancement of Voyager. “We are thrilled to be collaborating with foremost experts in Huntington’s disease and neurosurgical shipping of gene therapies as we start the prepared medical analysis of our promising prospect.”

Voyager’s VYTAL Phase 1/2 scientific trial is a dose escalation review to evaluate the basic safety and tolerability of VY-HTT01 in people with early manifest Huntington’s sickness. Secondary endpoints include things like disorder biomarkers and scientific result actions.

About Voyager Therapeutics

Voyager Therapeutics is a scientific-stage gene treatment corporation targeted on acquiring life-shifting solutions for intense neurological ailments. Voyager is fully commited to advancing the field of AAV gene treatment as a result of innovation and financial investment in vector engineering and optimization, producing, and dosing and shipping and delivery strategies. Voyager’s wholly owned and partnered pipeline focuses on intense neurological disorders for which successful new therapies are essential, which includes Parkinson’s disorder, Huntington’s sickness, Friedreich’s ataxia, and other significant neurological illnesses. For a lot more information on Voyager Therapeutics, make sure you go to the company’s web site at or abide by @VoyagerTx on Twitter and LinkedIn.

Forward-On the lookout Statements

This press launch incorporates forward-seeking statements for the uses of the safe harbor provisions underneath The Non-public Securities Litigation Reform Act of 1995 and other federal securities legal guidelines. The use of text these kinds of as “may,” “might,” “will,” “would,” “should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “undoubtedly,” “project,” “intend,” “future,” “potential,” or “continue,” and other related expressions are supposed to detect ahead-looking statements. For example, all statements Voyager can make relating to the initiation, timing, development, pursuits and aims of the VYTAL clinical demo of VY-HTT01, the skill of VY-HTT01 to achieve wide knock down of HTT mRNA in the course of the mind, the collaboration by Voyager with primary Huntington’s condition and neurosurgical specialists, and Voyager’s intentions and systems for the development of a gene therapy for Huntington’s illness are forward on the lookout statements.

All forward-on the lookout statements are based mostly on estimates and assumptions by Voyager’s administration that, though Voyager believes such ahead-seeking statements to be acceptable, are inherently uncertain. All forward-wanting statements are subject matter to challenges and uncertainties that might lead to genuine benefits to vary materially from people that Voyager expected. These types of threats and uncertainties incorporate, between other people, the skill to prepare for the initiation of the VYTAL clinical demo at clinical web sites, which include the capacity to get the overview by and acceptance of Institutional Assessment Boards and other essential institutional approvals at proposed medical web-sites, the potential to recruit and have interaction researchers, doctors and sufferers to take part in the VYTAL scientific trial, the means to agree to phrases, and to indication and put into action medical trial agreements and connected agreements with VYTAL clinical trial collaborators, the capacity to identify Huntington people who fulfill the eligibility specifications for the VYTAL medical trial, and the ability for Voyager to perform a scientific demo in a well timed way beneath pending Covid-19 pandemic protocols. These statements are also subject to a number of content threats and uncertainties that are described in Voyager’s Yearly Report on Kind 10-K filed with the Securities and Exchange Commission, as current by its subsequent filings with the Securities and Exchange Commission. All information and facts in the press launch is as of the date of this press launch, and any forward-on the lookout statement speaks only as of the date on which it was made. Voyager undertakes no obligation to publicly update or revise this information and facts or any ahead-seeking statement, no matter if as a end result of new details, long term gatherings or usually, other than as demanded by regulation.


[email protected]


Sheryl Seapy
[email protected]


Primary Logo